26 May 2020
Australian biotechnology company Ferronova Pty Ltd today closed a $3.5 million Series A financing round to fund clinical trials of its cancer tracing nanoparticle designed to find secondary cancer cells more accurately during cancer surgery.
The Advertiser - 30 October 2019
SA company Ferronova has produced its first tiny cancer tracers for their journey into the human
body in an attempt to find a new pathway to early detection of solid tumour cancers.
Ferronova’s specialist polymer-coated iron oxide nanoparticles, made to global standards at a lab in Mawson Lakes, will
be injected into cancer patients at the Royal Adelaide Hospital shortly, following key approvals.
The Advertiser - 13 November 2017
THE co-founder of an Adelaide medical devices company that eventually attracted millions from global equity giant KKR is now helping another start-up to raise money for its first human trials next year.
Signostics co-founder and former chief operating officer Stewart Bartlett has been named chief executive of Ferronova, a spin-out from the University of South Australia.
The Advertiser - 20 June 2016
A NEW spin-out company will receive funding support from international partners to commercialise a locally-developed medical device that helps in easier detection of cancers using magnetic tracers.
University of South Australia - 20 June 2016
Researchers at the University of South Australia’s Future Industries Institute will join forces with New Zealand based nanoparticle specialist Boutiq Science and major IP investor, Powerhouse Ventures to develop an improved system for cancer detection that relies on magnetic rather than radioactive tracers.
The Lead - 10 June 2016
An improved system for detecting cancers that uses magnetic rather than radioactive tracers has taken a major step towards commercialisation.